Cubist Systematic Strategies, LLC I Mab Transaction History

Cubist Systematic Strategies, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$3.08 - $7.39 $20,355 - $48,840	6,609 Added 22.71%	35,717 $123,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $4.86 $39,422 - $59,500	12,243 Added 72.59%	29,108 $121,000
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $339,157 - $1.04 Million	-84,578 Reduced 83.37%	16,865 $68,000
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $38,869 - $86,621	-4,700 Reduced 4.43%	101,443 $1.15 Million
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $1.32 Million - $4.96 Million	105,599 Added 19411.58%	106,143 $1.72 Million
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $278,743 - $458,622	-6,156 Reduced 91.88%	544 $26,000
Q3 2021 Nov 15, 2021	SELL	$57.18 - $84.43 $2.36 Million - $3.49 Million	-41,326 Reduced 86.05%	6,700 $486,000
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $1.73 Million - $3.03 Million	36,084 Added 302.16%	48,026 $4.03 Million
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $529,985 - $763,929	11,942 New	11,942 $579,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.1M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.